All the news Showing 10 of 565 articlesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources New Fibrosis People with HIV are at risk for liver fibrosis and steatosis Michael Carter / 1 hour ago Metabolic syndrome, type 2 diabetes and obesity are risk factors for the development of liver fibrosis and steatosis (liver fat accumulation) in people living with HIV, including those who do ... Fibrosis Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV Michael Carter / 17 August 2017 Switching to raltegravir from efavirenz is associated with significant improvements in liver steatosis for HIV-positive people with non-alcoholic fatty liver disease, Spanish investigators report in the online edition of Clinical ... Treatment outcomes Treatment with DAAs reduces the risk of mortality in the first 18 months after the completion of treatment Michael Carter / 10 August 2017 For the first time, a large study has demonstrated that treatment with direct-acting antivirals (DAAs) significantly reduces mortality rates among people with hepatitis C virus (HCV) monoinfection. The study – ... Pan-genotypic regimens European and US regulators approve AbbVie's new combo for all hepatitis C genotypes Liz Highleyman / 08 August 2017 The European Commission and the US Food and Drug Administration (FDA) last week approved AbbVie's new combination pill for people with hepatitis C virus (HCV) genotypes 1 to 6, to ... Pharmaceutical industry Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows Keith Alcorn / 27 July 2017 HIV, hepatitis B and C and tuberculosis (TB) can each be treated for less than $90 a year where generic drugs can be made available, Dzintars Gotham of Imperial College, London, reported ... Treatment for people living with HIV and HCV Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection Liz Highleyman / 26 July 2017 AbbVie's new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society ... Access to medicines & diagnostics Hepatitis C treatment is effective and feasible in Africa Liz Highleyman / 25 July 2017 Treatment for hepatitis C in sub-Saharan Africa can produce cure rates as high as those seen in industrialised countries, with high adherence and minimal side-effects, according to a presentation yesterday at the ... Pan-genotypic regimens US regulator approves Gilead's Vosevi combo pill for hepatitis C retreatment Liz Highleyman / 19 July 2017 On 18 July the US Food and Drug Administration (FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" ... Fibrosis Non-alcoholic fatty liver disease common in people living with HIV – metabolic disorders are key risk factors Michael Carter / 19 July 2017 Over a third of people with HIV have non-alcoholic fatty liver disease (NAFLD) in the absence of hepatitis B or C, according to the results of a meta-analysis and systematic ... Disease course and symptoms HCV therapy with SVR reduces the risk of several non-liver-related diseases commonly seen in people with chronic HCV Michael Carter / 06 July 2017 The risk of several non-liver complications associated with chronic hepatitis C virus (HCV) infection is reduced after interferon-based treatment that achieves a sustained virological response (SVR), investigators from the United ... ← First12345...57Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds